Clinical trials: Perioperative Immunotherapy
Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative…
- Trial name
- VOLGA (NCT04960709)
- Testing
- Durvalumab, Tremelimumab, Enfortumab Vedotin
- Where
- 196 sites in United States, Argentina and 23 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery.
- Trial name
- NCT07718139
- Testing
- nivolumab, pembrolizumab, durvalumab
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb